MAOA
monoamine oxidase A
Gene summary
A protein-coding gene on chromosome X (drug metabolism (phase i), neurotransmission). This gene is one of two neighboring gene family members that encode mitochondrial enzymes which catalyze the oxidative deamination of amines, such as dopamine, norepinephrine, and serotonin. Mutation of this gene results in Brunner syndrome.
Source: NCBI Gene, accessed 2026-10-07.
Protein reference (UniProt)
- Protein
Amine oxidase [flavin-containing] A
- Function
Catalyzes the oxidative deamination of primary and some secondary amine such as neurotransmitters, with concomitant reduction of oxygen to hydrogen peroxide and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. Preferentially oxidizes serotonin. Also catalyzes the oxidative deamination of kynuramine to 3-(2-aminophenyl)-3-oxopropanal that can spontaneously condense to 4-hydroxyquinoline (By similarity).
- Subcellular location
Mitochondrion outer membrane.
- Tissue specificity
Heart, liver, duodenum, blood vessels and kidney.
- Associated conditions
Brunner syndrome (BRNRS).
Source: UniProtKB/Swiss-Prot P21397, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.
Why its pathway is in the library
Phase I enzymes determine exposure to finasteride, SSRIs, and other implicated drugs; variation here shapes the likelihood and persistence of adverse effects. Monoamine, GABA, glutamate, and cholinergic systems are the direct pharmacologic targets of SSRIs/SNRIs (PSSD) and the downstream effectors of neurosteroid signaling (PFS).
Written for the whole drug metabolism / neurotransmission family, not for MAOA specifically.
Mentioned in 1 corpus record
- Conference abstractPSSD Discord pick
Paroxetine-induced dopamine dysregulation: insights into the pathogenesis of post-SSRI sexual dysfunction (PSSD)
S Giatti, G Chrostek, L Cioffi, S Diviccaro, F Sanna, R C Melcangi · The Journal of Sexual Medicine
Congress abstract (J Sex Med Vol 22, Suppl 2, May 2025) extending the Melcangi group's paroxetine work into dopamine signaling: adult male rats treated with paroxetine for 14 days showed significantly reduced dopamine in nucleus accumbens both 24 h after…
DRD1DRD2MAOASLC18A2THDISC-0152025PSSDPSSD Discord picks
Also in drug metabolism (phase i)
All 23 genes- CYP2D6
cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)
chr 22· Drug metabolism· 6 records - COMT
catechol-O-methyltransferase
chr 22· Drug metabolism· 4 records - CYP3A4
cytochrome P450 family 3 subfamily A member 4
chr 7· Drug metabolism· 2 records - CYP2C19
cytochrome P450 family 2 subfamily C member 19
chr 10· Drug metabolism· 1 record - CYP3A5
cytochrome P450 family 3 subfamily A member 5
chr 7· Drug metabolism· 1 record - AKR1B1
aldo-keto reductase family 1 member B
chr 7· Drug metabolism· Pathway candidate - AKR1B10
aldo-keto reductase family 1 member B10
chr 7· Drug metabolism· Pathway candidate - ALDH1A1
aldehyde dehydrogenase 1 family member A1
chr 9· Drug metabolism· Pathway candidate
Browse by family on the gene families page.